JP2016520528A5 - - Google Patents

Info

Publication number

JP2016520528A5

JP2016520528A5 JP2016503094A JP2016503094A JP2016520528A5 JP 2016520528 A5 JP2016520528 A5 JP 2016520528A5 JP 2016503094 A JP2016503094 A JP 2016503094A JP 2016503094 A JP2016503094 A JP 2016503094A JP 2016520528 A5 JP2016520528 A5 JP 2016520528A5

Authority

JP

Japan

Prior art keywords

cancer

combination

kdm5

composition

antagonist

Prior art date

2014-03-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012830 cancer therapeutic Substances 0.000 claims description 42
• 239000005557 antagonist Substances 0.000 claims description 36
• 206010028980 Neoplasm Diseases 0.000 claims description 33
• 201000011510 cancer Diseases 0.000 claims description 33
• 229940124597 therapeutic agent Drugs 0.000 claims description 29
• 238000002626 targeted therapy Methods 0.000 claims description 14
• 238000011282 treatment Methods 0.000 claims description 12
• 101001088883 Homo sapiens Lysine-specific demethylase 5B Proteins 0.000 claims description 10
• 102100033247 Lysine-specific demethylase 5B Human genes 0.000 claims description 10
• 238000002512 chemotherapy Methods 0.000 claims description 10
• 239000003112 inhibitor Substances 0.000 claims description 10
• 101001088892 Homo sapiens Lysine-specific demethylase 5A Proteins 0.000 claims description 8
• 102100033246 Lysine-specific demethylase 5A Human genes 0.000 claims description 8
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 8
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
• 201000005202 lung cancer Diseases 0.000 claims description 5
• 208000020816 lung neoplasm Diseases 0.000 claims description 5
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
• 230000035945 sensitivity Effects 0.000 claims description 5
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 229940122558 EGFR antagonist Drugs 0.000 claims description 4
• 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 claims description 4
• 101001088879 Homo sapiens Lysine-specific demethylase 5D Proteins 0.000 claims description 4
• 102100033249 Lysine-specific demethylase 5C Human genes 0.000 claims description 4
• 102100033143 Lysine-specific demethylase 5D Human genes 0.000 claims description 4
• 229940123237 Taxane Drugs 0.000 claims description 4
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical group C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
• 150000003384 small molecules Chemical class 0.000 claims description 4
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
• 206010009944 Colon cancer Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 230000012010 growth Effects 0.000 claims description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
• 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims description 2
• 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
• 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims description 2
• 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
• 239000012828 PI3K inhibitor Substances 0.000 claims description 2
• 229930012538 Paclitaxel Natural products 0.000 claims description 2
• 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 2
• 230000005907 cancer growth Effects 0.000 claims description 2
• 230000010261 cell growth Effects 0.000 claims description 2
• 229960003668 docetaxel Drugs 0.000 claims description 2
• 230000000694 effects Effects 0.000 claims description 2
• 229960001433 erlotinib Drugs 0.000 claims description 2
• 229960001592 paclitaxel Drugs 0.000 claims description 2
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 2
• 229910052697 platinum Inorganic materials 0.000 claims description 2
• 108091033319 polynucleotide Proteins 0.000 claims description 2
• 102000040430 polynucleotide Human genes 0.000 claims description 2
• 239000002157 polynucleotide Substances 0.000 claims description 2
• 229920001184 polypeptide Polymers 0.000 claims description 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
• 150000003839 salts Chemical class 0.000 claims description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
• 229960003862 vemurafenib Drugs 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 44
• 238000011275 oncology therapy Methods 0.000 claims 4
• 239000003560 cancer drug Substances 0.000 claims 3
• 239000013066 combination product Substances 0.000 claims 3
• 229940127555 combination product Drugs 0.000 claims 3
• 238000009472 formulation Methods 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 43
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 1